Nixon et al., 2017 - Google Patents
Alterations in sarcomere function modify the hyperplastic to hypertrophic transition phase of mammalian cardiomyocyte developmentNixon et al., 2017
View HTML- Document ID
- 9071748027321357504
- Author
- Nixon B
- Williams A
- Glennon M
- de Feria A
- Sebag S
- Baldwin H
- Becker J
- Publication year
- Publication venue
- JCI insight
External Links
Snippet
It remains unclear how perturbations in cardiomyocyte sarcomere function alter postnatal heart development. We utilized murine models that allowed manipulation of cardiac myosin- binding protein C (MYBPC3) expression at critical stages of cardiac ontogeny to study the …
- 210000004413 Myocytes, Cardiac 0 title abstract description 204
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6802—General aspects
- C12Q1/6809—Sequence identification involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ranek et al. | PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress | |
| Gao et al. | The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N 6-methyladenosine methylation of Parp10 mRNA | |
| Guimarães-Camboa et al. | HIF1α represses cell stress pathways to allow proliferation of hypoxic fetal cardiomyocytes | |
| Vieira et al. | BRG1-SWI/SNF-dependent regulation of the Wt1 transcriptional landscape mediates epicardial activity during heart development and disease | |
| Chen et al. | Targeted inactivation of murine Ddx3x: essential roles of Ddx3x in placentation and embryogenesis | |
| Bick et al. | Cardiovascular homeostasis dependence on MICU2, a regulatory subunit of the mitochondrial calcium uniporter | |
| Affar et al. | Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression | |
| Wang et al. | APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p | |
| Liu et al. | Overexpression of miR-142-3p improves mitochondrial function in cardiac hypertrophy | |
| Yang et al. | Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells | |
| Hille et al. | Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling | |
| Yu et al. | The m7g methyltransferase mettl1 drives cardiac hypertrophy by regulating srsf9‐mediated splicing of nfatc4 | |
| Becker-Weimann et al. | NFkB disrupts tissue polarity in 3D by preventing integration of microenvironmental signals | |
| Tsai et al. | Genome-wide screening identifies a KCNIP1 copy number variant as a genetic predictor for atrial fibrillation | |
| Dai et al. | Smooth muscle cell-specific FoxM1 controls hypoxia-induced pulmonary hypertension | |
| Awad et al. | Control of histone H3 phosphorylation by CaMKII δ in response to haemodynamic cardiac stress | |
| Aonuma et al. | Cardiomyocyte microRNA-150 confers cardiac protection and directly represses proapoptotic small proline–rich protein 1A | |
| Williams et al. | HIF-1 regulation of miR-29c impairs SERCA2 expression and cardiac contractility | |
| Nixon et al. | Alterations in sarcomere function modify the hyperplastic to hypertrophic transition phase of mammalian cardiomyocyte development | |
| Fan et al. | Ca2+/calmodulin-dependent protein kinase II (CaMKII) increases small-conductance Ca2+-activated K+ current in patients with chronic atrial fibrillation | |
| Liu et al. | Genetic analysis of Down syndrome-associated heart defects in mice | |
| Chen et al. | Inhibition of TREM-1 ameliorates angiotensin II-induced atrial fibrillation by attenuating macrophage infiltration and inflammation through the PI3K/AKT/FoxO3a signaling pathway | |
| Liu et al. | Regulation of the muscarinic M3 receptor by myocardin-related transcription factors | |
| Nakamura et al. | PDK1 regulates cell proliferation and cell cycle progression through control of cyclin D1 and p27Kip1 expression | |
| Lin et al. | Circular RNA circ_0001006 aggravates cardiac hypertrophy via miR-214-3p/PAK6 axis |